XOMA (XOMA) Reports Improvement in Diabetes and Inflammatory Measures in Animal Model With XOMA 052

June 8, 2009 4:38 PM EDT

XOMA Ltd. (Nasdaq: XOMA) announced the presentation of new preclinical results with XOMA 052 in the diet-induced obesity mouse model. XOMA 052 addresses the inflammatory cause of Type 2 diabetes by targeting interleukin 1 beta (IL-1 beta), a master signaling protein which triggers inflammatory pathways.

Groups of mice received either a normal diet or a high fat/high sucrose diet and twice-weekly doses of XOMA 052 or an isotype control for 12 to 14 weeks. This study design enabled evaluation of XOMA 052 in both normal and simulated diabetic conditions. At the end of the study period, mice that received XOMA 052 and the high fat/high sucrose diet showed, as compared to control (mice receiving isotype control and on high fat/high sucrose diet), statistically significant:

• Reduction in glycosylated hemoglobin (HbA1c) levels
  
• Reduction in fasting blood glucose without causing hypoglycemia
  
• Improvement in glucose control
  
• Improvement in insulin secretion and beta cell function
  
• Protection from diet-induced beta cell apoptosis
  
• Increase in beta cell proliferation
  
• Reduction in total cholesterol without reduction in high density lipoprotein
  
• Reduction in triglycerides and free fatty acids

More from Release

Related Categories

FDA

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?